# Lecture 05: Antipsychotics

## Dopamine Hypothesis
**Excessive dopaminergic activity in the mesolimbic system** causes psychosis

---

## CNS Dopamine Tracts

| Tract | Effect of Reduced DA |
|-------|---------------------|
| **Tuberoinfundibular** | ↑ Prolactin release |
| **Nigrostriatal** | Acute EPS, Tardive Dyskinesia, NMS |
| **Mesolimbic-Mesocortical** | ↓ Positive symptoms; ↑ Negative symptoms |

---

## Symptoms of Schizophrenia

| Positive Symptoms (Additions) | Negative Symptoms (Subtractions) |
|------------------------------|----------------------------------|
| Thought disorders | Amotivation |
| Delusions | Social withdrawal |
| Hallucinations | Flat affect |
| Paranoia | Poverty of speech |

---

## Antipsychotic Classes

### First Generation (Typical) Antipsychotics

| Property | Details |
|----------|---------|
| **MOA** | D2 antagonism |
| **Side effects** | H1, mACh, Alpha-1 (varies by potency) |
| **EPS risk** | Higher |

#### Potency Spectrum

| Potency | EPS Risk | Off-Target Effects | Example |
|---------|----------|-------------------|---------|
| **High potency** | HIGH | LOW | **Haloperidol** |
| **Low potency** | LOW | HIGH | **Chlorpromazine** |

*Can add anticholinergic drug to balance EPS with high-potency typicals*

---

### Second Generation (Atypical) Antipsychotics

#### SDAs (Serotonin-Dopamine Antagonists)
| Property | Details |
|----------|---------|
| **MOA** | D2 antagonism + 5-HT2a antagonism |
| **Examples** | **Risperidone**, **Olanzapine** |
| **Side effects** | Variable (metabolic syndrome common) |
| **EPS risk** | Lower |
| **Other uses** | Mood disorders, depression |

#### DRPAs (Dopamine Receptor Partial Agonists)
| Property | Details |
|----------|---------|
| **MOA** | D2 partial agonism + 5-HT2a antagonism |
| **Example** | **Aripiprazole** |
| **Advantage** | Less EPS, less metabolic effects |

#### Muscarinic Agonist Antipsychotics
| Property | Details |
|----------|---------|
| **MOA** | M1/M4 agonism |
| **Drugs** | **Xanomeline + Trospium** |
| **Note** | Trospium is non-selective muscarinic antagonist that does NOT cross BBB |

---

### Clozapine (Unique)

| Property | Details |
|----------|---------|
| **MOA** | D1, D4, multiple 5-HT subtypes, multiple mACh subtypes; **minimal D2 affinity** |
| **Unique benefit** | **Only drug effective for NEGATIVE symptoms** |
| **EPS** | **NONE** |

#### Toxicities
- **Agranulocytosis** (requires monitoring)
- Severe constipation
- Sialorrhea (excessive salivation)
- Seizure risk

---

## Extrapyramidal Side Effects (EPS)

Localized to D2 inhibition in **basal ganglia** (nigrostriatal pathway)

### EPS Progression (Time Course)

| Order | Effect | Timing |
|-------|--------|--------|
| 1 | **Acute dystonia** | Hours to days |
| 2 | **Akathisia** | Days to weeks |
| 3 | **Parkinsonism** | Weeks to months |
| 4 | **Tardive dyskinesia** | Months to years |

**Mnemonic**: **A**cute dystonia → **A**kathisia → **P**arkinsonism → **T**ardive dyskinesia

---

## Neuroleptic Malignant Syndrome (NMS)

### Mechanism
- Excess dopamine regulation (too little nigrostriatal pathway activity)

### Clinical Features
- **Muscle rigidity**
- **Delirium**
- **Hyperthermia**
- Autonomic instability

### Labs
- **↑ CPK** (rhabdomyolysis)
- **↑ K+**
- **↑ Lactic acid**

### Treatment
- Stop antipsychotic
- **Dantrolene** (muscle relaxant)
- Supportive care

---

## Summary Table: Antipsychotics

| Type | MOA | Examples | EPS | Key Point |
|------|-----|----------|-----|-----------|
| **Typical (High Potency)** | D2 antagonist | Haloperidol | High | Low off-target effects |
| **Typical (Low Potency)** | D2 antagonist | Chlorpromazine | Low | High off-target effects |
| **Atypical (SDA)** | D2 + 5-HT2a antagonist | Risperidone, Olanzapine | Lower | Metabolic syndrome |
| **Atypical (DRPA)** | D2 partial agonist | Aripiprazole | Lower | Less metabolic effects |
| **Clozapine** | D1, D4, 5-HT, mACh | Clozapine | None | Only for negative symptoms; agranulocytosis |

---

## Key High-Yield Points

1. **Antipsychotics primarily reduce POSITIVE symptoms** via D2 antagonism
2. **Clozapine** is the only drug good for **negative symptoms** and has **no EPS**
3. **High potency typicals** = high EPS, low off-target
4. **Low potency typicals** = low EPS, high off-target
5. **NMS** = rigidity + delirium + hyperthermia + elevated CPK
6. **EPS order**: Acute dystonia → Akathisia → Parkinsonism → Tardive dyskinesia
